AMEX:OGEN (USA) Also trade in: Germany

Oragenics Inc

$ 0.55 0.07 (15.86%)
Volume: 4,612,009 Avg Vol (1m): 1,797,940
Market Cap $: 25.41 Mil Enterprise Value $: 2.65 Mil
P/E (TTM): 0.00 P/B: 0.76
Earnings Power Value 1.15
Net Current Asset Value 0.73
Tangible Book 0.74
Projected FCF -1.99
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 6/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 376.27
Cash-To-Debt ranked higher than
50.46% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
OGEN: 376.27
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.02, Med: 76.82, Max: 10000
Current: 376.27
0.02
10000
Debt-to-EBITDA -0.01
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
OGEN: -0.01
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -0.25, Med: -0.01, Max: 0
Current: -0.01
-0.25
0
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.75
DISTRESS
GREY
SAFE
Beneish M-Score -13.56
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -15436.99%
WACC 14.36%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
ROE % -87.09
ROE ranked lower than
92.11% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
OGEN: -87.09
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -2486.23, Med: -155.45, Max: -44.24
Current: -87.09
-2486.23
-44.24
ROA % -69.86
ROA ranked lower than
91.51% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
OGEN: -69.86
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -512.79, Med: -138.78, Max: -41.41
Current: -69.86
-512.79
-41.41
ROC (Joel Greenblatt) % -4327.88
ROC (Joel Greenblatt) ranked lower than
63.32% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
OGEN: -4327.88
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -28662.5, Med: -5780.21, Max: -406.31
Current: -4327.88
-28662.5
-406.31
3-Year Total EBITDA Growth Rate 5.50
3-Year EBITDA Growth Rate ranked higher than
52.62% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
OGEN: 38.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 2, Med: 24.5, Max: 49.9
Current: 38.1
2
49.9
3-Year EPS w/o NRI Growth Rate 35.20
3-Year EPS w/o NRI Growth Rate ranked lower than
51.51% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
OGEN: 35.2
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 24.2, Max: 50.8
Current: 35.2
0
50.8

» OGEN's 30-Y Financials

Financials (Next Earnings Date: )

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with AMEX:OGEN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare ASX:AHZ NAS:LIFE OTCPK:IPIX NAS:NVLN AMEX:NAVB ASX:ACR XKRX:281310 NAS:ONTX AMEX:RNN ASX:IVQ NAS:ADIL OTCPK:CDXI XCNQ:NSHS OSL:BIOTEC BOM:540679 OTCPK:ETST ASX:EX1 LSE:HVO NAS:CTXR XSAT:SPAG
Traded in other countries UAVP.Germany
Address 4902 Eisenhower Boulevard, Suite 125, Tampa, FL, USA, 33634
Oragenics Inc is engaged in the healthcare sector. The firm is focused on becoming a leader in developing novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics involves in developing its antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and have other product candidates, including SMaRT Replacement Therapy positioned for outlicensing or partnering.

Ratios

Current vs industry vs history
PB Ratio 0.76
PB Ratio ranked lower than
100.00% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
OGEN: 0.76
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.35, Med: 5.34, Max: 258.9
Current: 0.76
0.35
258.9
EV-to-EBIT -0.17
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
OGEN: -0.17
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -14.3, Med: -3, Max: 0.3
Current: -0.17
-14.3
0.3
EV-to-EBITDA -0.17
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
OGEN: -0.17
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -14.9, Med: -3, Max: 0.3
Current: -0.17
-14.9
0.3
Current Ratio 14.22
Current Ratio ranked higher than
51.86% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
OGEN: 14.22
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.09, Med: 4.22, Max: 28.76
Current: 14.22
0.09
28.76
Quick Ratio 14.22
Quick Ratio ranked higher than
54.38% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
OGEN: 14.22
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.06, Med: 4.22, Max: 28.76
Current: 14.22
0.06
28.76

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -48.40
3-Year Share Buyback Rate ranked higher than
57.06% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
OGEN: -48.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -84.8, Med: -45.9, Max: -10.8
Current: -48.4
-84.8
-10.8

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 0.74
Price-to-Tangible-Book ranked lower than
100.00% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
OGEN: 0.74
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.64, Med: 10.95, Max: 2350
Current: 0.74
0.64
2350
Earnings Yield (Joel Greenblatt) % -400.09
Earnings Yield (Greenblatt) ranked lower than
92.69% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
OGEN: -400.09
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -21381.5, Med: -30.35, Max: 7688.41
Current: -400.09
-21381.5
7688.41

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N